Other OTC - Delayed Quote USD

Cardax, Inc. (CDXI)

0.0000 0.0000 (0.00%)
At close: December 27 at 9:38 AM EST

Key Executives

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. David G. Watumull Chairman & CEO 214.96k -- 1950
Mr. David M. Watumull COO & CFO 162.11k -- 1982
Mr. Gilbert Shin Vice President of Retail Sales & Marketing -- -- --

Cardax, Inc.

2800 Woodlawn Drive
Suite 129
Honolulu, HI 96822
United States
808 457 1400 https://www.cardaxpharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
10

Description

Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.

Corporate Governance

Cardax, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Jan 15, 2020
    Dividend Date

Upcoming Events